News
-
-
-
-
-
PRESS RELEASE
Ondine Biomedical Inc - Microbiome Research Supports Use of Steriwave
Ondine Biomedical's research at the SPIE Photonics West conference shows that its Steriwave® Nasal Photodisinfection System significantly reduces nasal pathogens without causing long-term harm to the nasal microbiome, offering a non-selective method of nasal decolonization with rapid recovery of the native microbiome post-treatment -
PRESS RELEASE
Ondine Unveils New Research at SPIE Photonics West
Ondine Biomedical Inc. will present new research on photodisinfection and nasal decolonization at the SPIE Photonics West conference in San Francisco, California. The presentation will showcase the effectiveness of Steriwave as a nasal decolonization method. -
PRESS RELEASE
Ondine Biomedical Inc. Announces Appointment of new Chief Financial Officer
Ondine Biomedical Inc., a Canadian life sciences company, has appointed Joseph P. Errico as Chief Financial Officer. With a background in founding and selling medical device and pharmaceutical companies, Errico brings valuable experience in finance, capital markets, and developing medtech companies. His appointment comes at a crucial time as Ondine pursues international expansion and FDA approval. Errico's educational background includes a degree in Aeronautical Engineering from MIT and graduate degrees in Law and Mechanical/Materials Engineering from Duke University. Ondine Biomedical Inc. is innovating in photodisinfection therapies with products approved in multiple jurisdictions. For further information, please visit www.rns.com. -
-
-
![Accesswire](/assets/images/accesswire-inline.png)
-
Southern Energy Corp. Announces Payment of Interest in-Kind to its 8% Convertible Unsecured Subordinated Debentures
-
APWG 2024 Cybercrime Research Conference Extends Submission Deadline to July 7
-
Product Creation Studio Partners With PatchClamp Medtech Inc. to Develop Revolutionary Dural Repair System
-
XS Financial Enters Into Definitive Agreement to Be Taken Private
-
TRU Engages Investor Relations Specialists HE Capital Markets
![EQS Group](/assets/images/eqs-group.png)
-
DEFENCE’S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED OVARIAN CANCER RESULTING IN COMPLETE RESPONSES IN TREATED ANIMALS
-
Agreement reached with iBusiness Funding to acquire Funding Circle’s US business
-
Cairn Homes Plc: Transaction in Own Shares
-
Just – Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization Program
-
HORNBACH Group delivers strong Q1 2024/25 results increasing earnings per share y-o-y by 44% – full-year outlook confirmed unchanged
![Les Echos](/assets/images/les-echos.png)
-
Cie du Bois Sauvage: Buy back of own shares – week from 17/06/2024 to 21/06/2024
-
Signing of the share purchase agreement for the acquisition of a majority stake in Neoen by Brookfield from Impala and other shareholders and of a tender agreement between Brookfield and Bpifrance
-
Schneider Electric launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2031 for a nominal amount of €750 million and a concurrent repurchase of its outstanding OCEANEs due 2026
-
Gimv increases its stake in TINC – Gimv and Belfius conclude agreement in principle on the sale of the shares of Belfius Insurance in TINC
-
Disclosure of Share Capital and Voting Rights Outstanding as of May 31, 2024